Browse Articles

Discover research articles across all indexed journals

VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy.

Journal of Clinical Oncology Yu Shen, Xingming Zhang, Xinyuan Wei et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps616

TPS616 Background: Despite substantial advances in therapy over the past 20 years, the median progression-free survival (mPFS) for advanced RCC patients treated with first-line tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) remains around 20 months (Motzer RJ et al., NEJM 2021, Choueiri TK et al., NEJM 2021). Moreover, subsequent treatments post-first-line progression exhibit inadequate efficacy. A phase Ib/II single-arm trial achieved a high objective response rate (ORR) with lenvatinib plus pembrolizumab in patients post-ICI progression (Lee CH et al., Lancet Oncol 2021). However, other trials showed that ICIs did not benefit advanced RCC patients who have progressed after receiving ICIs (Pal SK et al., Lancet 2023, Choueiri TK, et al., Lancet 2024). The failures of previous ICI re-challenges may be related to the limited efficacy of PD-L1 blockade (atezolizumab) in RCC and the reduced dosage of tivozanib, whose efficacy is closely related to its blood concentration. So we designed a trial to assess the efficacy and safety of the full-dose TKI vorolanib, with favorable safety profiles, combined with the PD-1 inhibitor sintilimab in advanced RCC patients who have failed prior immune combination therapy. Methods: VORSIN-RCC is a prospective, multicenter, single-arm, phase II study enrolling patients with pathologically confirmed RCC. It includes individuals with metastatic or stage IV disease (2017 AJCC 8th edition TNM staging system) who have progressed on prior targeted combination immunotherapy, dual checkpoint inhibitor therapy, or immune monotherapy. Based on historical data, the mPFS for advanced RCC patients previously treated with immune-based combination therapy is approximately 7.96 months for targeted therapy alone and 10.6 to 12.2 months for combined targeted and immunotherapy. Using these figures, with a reference mPFS (m 0 ) of 7.96 months and a desired mPFS (m 1 ) of 11.2 months, the sample size was calculated for a 24-month enrollment period and a total trial duration of 36 months. A one-sided significance level (α) of 0.05, power of 0.8018, dropout rate of 10%, and a Weibull distribution shape parameter (k) of 1 were used. The sample size was determined using PASS software with a one-sample log-rank test estimation method, resulting in an expected sample size of 67 patients for this study. Enrolled patients will receive oral vorolanib tablets (200 mg/day) combined with intravenous sintilimab (400 mg every 3 weeks). The primary endpoint is PFS. Secondary endpoints include ORR, overall survival (OS), adverse events (AEs), disease control rate (DCR), duration of response (DoR), patient quality of life (QoL), and pain score. Both ORR and DCR are assessed using RECIST 1.1 and imRECIST criteria. This study is actively recruiting. Research Sponsor: Hao Zeng. Clinical trial information: NCT06523049 .

Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program (EAP).

Journal of Clinical Oncology Deniz Tural, Oğuzcan Özkan, Sendag Yaslikaya et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.708

708 Background: This study evaluates the real-world efficacy and safety of avelumab maintenance therapy in metastatic urothelial carcinoma (mUC) patients who have not progressed following first-line platinum chemotherapy, using data from the EAP. Methods: The primary endpoint was the overall survival (OS), progression-free survival (PFS) and secondary endpoints included safety. PFS and OS were estimated by using the Kaplan-Meier method. Results: One hundred seventeen patients who received at least one cycle of Avelumab. The median number of first-line platinum-based chemotherapy cycles was 5 (range, 3-6). Patients’ characteristics were illustrated in Table 1. The median follow-up was 12.1 months. The 12-month OS rate was 78% (95% CI, 74.5%-79%), while the median OS was not reached. The 12-month PFS rate was 32% (95% CI, 29%-35%) and the median PFS was 5.3 months (95% 3.4–7.1). In univariate analysis, the median PFS were 2.9 vs 5.4 months in patients with or without liver metastases (p=0.001) and 2.8 vs 5.3 months, in patients with hemoglobin levels below or higher than 10 mg/dl(p=0.06), 8.8 vs 4.1 months in patients with lymph nodes only versus other site metastases(p=0.05), respectively. However, the median PFS were 5.6 vs 4.9 months in first-line cisplatin base chemotherapy versus carboplatin (p=0.7), 7.3 versus 4.9 months in 4≤ cycle chemotherapy versus 4 >cycle(p=0.4), and 5.7 versus 5.3 months in response to first line chemotherapy (CR vs PR and Stabil response) (p=0.4) were not statistically significant for PFS. Thirty-one percent of patients experienced a treatment-related adverse event of any grade, and 9 (7.6%) of patients had a grade 3–4 treatment-related adverse event. Conclusions: Avelumab demonstrated effectiveness and tolerability as a maintenance treatment for mUC patients who had not progressed following first-line platinum-based chemotherapy regardless of first line chemotherapy regimen, chemotherapy cycles and response to first line chemotherapy. Liver metastases, only lymph node metastases and hemoglobin level significant factors on PFS. Patient Characteristics (n=117) n % Age (median, years) : 66 (43-84) Male Sex 94 80.3 Site of Primary Tumor Bladder 93 79.5 Renal Pelvis 12 10.3 Ureter 10 8.5 Urethra 2 1.7 Histological Subtype Urothelial Carcinoma 112 95.7 Mixed Histology (urothelial+variant) 5 4.3 ECOG-PS 0 51 43.5 1 64 54.8 2 2 1.7 Baseline Creatinine Clearance <60 ml/min 48 41 Baseline Hemoglobin concentration <10 g/dl 18 15.4 Tobacco Use Current 16 13.7 Previous 70 59.8 Never 24 20.5 Unknown 7 6 Metastatic Site at Baseline Visceral 79 67.5 Liver 9 7.7 Lymph Node Only 42 35.9 Metastatic at the time of diagnosis 71 60.7 Neoadjuvant Chemotherapy 8 6.8 Cystectomy 60 51.3 Palliative/Curative Radiotherapy 13 11.1 Previous Chemotherapy Cisplatin-Gemcitabine 65 55.5 Carboplatin-Gemcitabine 47 40.2 ddMVAC 5 4.3

Circulating tumor cell RNA biomarker for bavdegalutamide (ARV-110) in metastatic castration-resistant prostate cancer without AR T878/H875 mutations.

Journal of Clinical Oncology Keisuke Otani, Xin Gao, Erika Kusaka et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.235

235 Background: Bavdegalutamide (bavdeg; formerly ARV-110) is a first-in-class oral proteolysis targeting chimera (PROTAC) protein degrader that selectively targets androgen receptor (AR). A phase 1/2 study of bavdeg showed clinical activity in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1-2 prior AR-targeted therapies, particularly in those harboring AR T878X/H875Y mutations. Although some patients with wildtype AR showed clinical benefit from bavdeg, no biomarker exists to select this subgroup of patients. Here we evaluated a circulating tumor cell (CTC) RNA biomarker for its potential to identify patients with mCRPC who may benefit from bavdeg in the phase 1/2 study despite the absence of AR T878X/H875Y mutations. Methods: Patients with mCRPC and disease progression after >1 prior novel hormonal agents were enrolled in the phase 1/2 study of bavdeg and consented for prospective collection of pre-treatment blood for CTC analysis at a single institution. CTCs were isolated using a negative selection microfluidic CTC enrichment device and analyzed for RNA expression of a panel of prostate cancer genes ( AGR2, FAT1, FOLH1, HOXB13, KLK2, KLK3, STEAP2, TMPRSS2, AR-V7 ) using a multiplex droplet digital PCR assay. A composite gene expression score (CTCm; Miyamoto et al. Cancer Discov. 2018) was compared to radiographic response at 2 months, PSA response, and duration of time on bavdeg. A cut-off value for CTCm was determined by receiver operating characteristic curve analysis. Association of CTCm with clinical outcomes was analyzed by two-sided Fisher’s exact test. Results: Twenty patients treated with bavdeg doses ranging from 280-700 mg daily and 140-420 mg twice daily consented to pre-treatment CTC RNA expression analysis. Circulating tumor DNA analyses revealed none of the patients harbored AR T878 or H875 mutations. Six patients remained on bavdeg >6 months with clinical benefit, while 14 discontinued therapy within 6 months. Radiographic responses at 2 months were stable, progressive, and not evaluable in 10, 7, and 3 patients, respectively. A best PSA decline ≥50% (PSA50) and ≥30% (PSA30) was achieved in 3 and 4 patients, respectively. Pre-treatment CTCm score <165 was associated with stable disease at 2 months (p = 0.015) and time on bavdeg >6 months (p = 0.014). CTCm did not correlate with PSA50 (p>0.9) or PSA30 (p=0.60). Presence of AR-V7 did not correlate with radiographic response (p=0.15), PSA50 (p>0.9), PSA30 (p=0.60), or time on therapy >6 months (p=0.14). Conclusions: Pre-treatment CTCm score <165 was associated with freedom from radiographic progression at 2 months and time on bavdeg >6 months in this small study mCRPC patients without AR T878/H875 mutations. Further investigation of the CTCm biomarker is warranted in mCRPC patients treated with bavdegalutamide and potentially other AR PROTACs.

[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients.

Journal of Clinical Oncology Francisco Osvaldo Garcia-Perez, Anna Scavuzzo, Irma Soldevilla-Gallardo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.34

34 Background: Prostate cancer represents a strong economic and social burden in the world. Imaging, pathology report and prostate specific antigen are the cornerstone for decision making. PSMA imaging with PET/CT has demonstrated superiority over conventional imaging, however, its availability is limited in countries with emerging economies. 99mTc-based imaging is widely used and has been favored by the development of new inhibitors targeting PSMA. Methods: We analyzed retrospectively 119 men with a histopathological diagnosis of prostate cancer obtained through transrectal biopsy or with clinical suspicion due to elevated PSA levels and physical examination findings. 68 were classified as high-risk and 51 as very high-risk, and referred for staging with [99mTc]Tc-iPSMA SPECT/CT between July 2022 and July 2024. The waiting times for initiating treatment were compared with a strategy based on PET/PSMA. Also number of lesions in patients with dual imaging with [99mTc]Tc-MDP and [99mTc]Tc-iPSMA was analyzed and assessed the changes in intention to treat. Results: Mean age of patients was 69.2 y/o (range 55-89 y/o), mean PSA level of staging group was 78.5 ng/mL (range 28.5-1667 ng/mL). Waiting time for a [99mTc]Tc-iPSMA was 7.2 days (+/- 1.5 days) versus 67.5 days (+/- 11.8 days) for [18F]F-iPSMA PSMA-1007. An additional study was required in 15.1% (n=18) of patients (n=13 PET/CT [18F]F PSMA-1007, 5 abdominal magnetic resonance). 36 patients had dual studies, observing 108 lesions with [99mTc]Tc-iPSMA and 114 with [99mTc]Tc-MDP, 6 with PSMA and 12 with MDP did not show anatomical changes. These findings did not modify the clinical stage or treatment intention. Overall, 590 lesions were identified in 119 patients, 101 in prostate, 267 in bone (diffuse disease in bone was considered as a single lesion), 135 in regional lymph nodes, and 87 in non-regional lymph nodes. Size range of lymph nodes detected were 0.5 mm to 25 mm. The change in management occurred in 23% patients (n=28); the changes were from ADT alone to doublet (ADT and Docetaxel) (n=11), from Radiotherapy to the pelvis to ADT + Docetaxel (n=8), from Radiotherapy to the pelvis to triplet (ADT+ Docetaxel + ARPi) (n=5), from ADT + RT to surgery (n=2), from ADT alone to ADT + SBRT (n=2). Conclusions: [99mTc]Tc-iPSMA SPECT/CT is an efficient alternative tool to [18F]F-iPSMA PSMA-1007, the results provide sufficient information to allow a significant change in intention to treat, significantly reducing waiting times, especially in countries where equipment availability PET is limited. These results support the development of public policies that promote the use of this type of radiopharmaceuticals to expand access to the new generation imaging modality and provide a benefit in the clinical management of prostate cancer especially in countries with low PET/CT infrastructure.

Evaluation of avelumab first-line (1L) maintenance therapy and subsequent treatment (tx) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) using a large claims database in Japan: JAVEMACS-D.

Journal of Clinical Oncology Takashi Kobayashi, Hiroshi Kitamura, Yuka Furukawa et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.700

700 Background: In Japan, avelumab was approved in Feb 2021 as maintenance therapy for pts with curatively unresectable UC that had not progressed after platinum-based chemotherapy (PBC) based on phase 3 data from JAVELIN Bladder 100 showing prolonged overall survival. We report initial data from JAVEMACS-D, a real-world study of pts who received avelumab 1L maintenance therapy using a large claims database in Japan (Medical Data Vision). Methods: JAVEMACS-D is a longitudinal, observational, retrospective study of adults with la/mUC who had received PBC and had a first dose of avelumab maintenance therapy between Feb 2021 and Apr 2023. Pt characteristics and tx patterns were analyzed using descriptive statistics. Results: 773 pts were included. Median observation period was 14.0 mo from start of avelumab and 20.2 mo from start of 1L PBC. Median age was 74 y (interquartile range [IQR], 69.0-79.0), and 189 pts (24.5%) were aged ≥80 y. Primary tumor location was bladder in 463 (59.9%) and renal pelvis/ureter in 330 (42.7%). Prior 1L PBC tx was gemcitabine (gem) + cisplatin (cis) in 474 (61.3%), gem + carboplatin (carbo) in 281 (36.4%), dose-dense MVAC in 8 (1.0%), and others in 10 (1.3%). Use of 1L gem + carbo was more common in pts aged ≥80 y (101/189 [53.4%]) or pts with a primary tumor in the renal pelvis/ureter (142/330 [43.0%]) vs the overall cohort. Number of PBC cycles was ≤3 in 139 (18.0%), 4 in 260 (33.6%), 5-6 in 224 (29.0%), and ≥7 in 150 (19.4%). Avelumab therapy was started in 2021 in 289 (37.4%) and in 2022 or later in 484 (62.6%). Receipt of ≥7 cycles of 1L PBC was less common in pts who started avelumab in 2022 or later vs 2021 (80 [16.5%] vs 70 [24.2%]). Median interval between PBC and avelumab was 5.0 wk (IQR, 3.6-6.9); the interval was <4 wk in 239 (30.9%), 4-10 wk in 474 (61.3%), and >10 wk in 60 (7.8%). At data cutoff (Oct 2023), 170 (22.0%) were still receiving avelumab, 394 (51.0%) had received second-line (2L) tx, and 209 (27.0%) discontinued avelumab without 2L tx. The most common 2L tx was enfortumab vedotin (EV) in 185 of 394 pts (47.0%), gem + cis/carbo in 122 (31.0%), and pembrolizumab in 65 (16.5%); 2L EV was more common in pts who started avelumab in 2022 or later vs 2021 (123/221 [55.7%] vs 62/173 [35.8%]). The most common third-line tx after 2L EV (n=40) was pembrolizumab in 19 (47.5%) and gem + cis/carbo in 18 (45.0%). Conclusions: JAVEMACS-D provides the largest real-world dataset of pts in Japan with la/mUC treated with avelumab maintenance therapy to date. The number of prior PBC cycles was generally 6 or lower in pts who started avelumab in 2022 or later. Although pts treated with avelumab were not resistant to PBC, EV was more common than PBC as 2L tx after avelumab, particularly in pts treated more recently, highlighting the evolving tx landscape.

Phase Ib/II clinical trial of oncolytic virus intravesical irrigation for preventing recurrence after TURBT in patients with recurrent high-risk NMIBC.

Journal of Clinical Oncology Youyan Guan, Xingang Bi, Hongzhe Shi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.763

763 Background: Oncolytic virus therapy represents a novel approach in cancer treatment, showing promising results in non-muscle-invasive bladder cancer (NMIBC). OH2 injection is a recombinant oncolytic virus, derived from genetically modified HSV-2 strain HG52, which is confirmed efficacy in certain malignant tumors. This clinical trial aims to evaluate the safety and preliminary efficacy of using OH2 injection solution for intravesical irrigation to prevent recurrence in patients with high-risk NMIBC who have failed first-line preventive irrigation therapy. Methods: This study included pathology confirmed high-risk NMIBC patients who had undergone TURBT after failing first-line preventive bladder irrigation therapy and had been confirmed to be free of tumor residue. To be eligible for enrollment, patients needed to have adequate organ function, an ECOG performance status of 2 or less, and be ineligible for or refused radical cystectomy. Those with muscle invasive or locally advanced metastatic bladder cancer were excluded. Following enrollment, patients received OH2 with normal saline intravesical irrigation. The irrigation was given every two weeks for 5 times, followed the sixth irrigation after 3 weeks, then once a month till a year. We evaluated the 6-month and 12-month recurrence-free survival (RFS) rates and safety following the administration of oncolytic virus irrigation during the induction and maintenance treatment. Results: Thirty patients were planned to enroll in this clinical trial. The data of 9 high risk NMIBC patients could be analyzed at this time. Most of the patients (6 out of 9) received BCG treatment before. The 6-month RFS rate was 66.7%, the 12-month RFS rate was 55.6%, and the median RFS was 353 days. One patient who failed after the BCG treatment had the long RFS nearly 2 years. In terms of safety, adverse effects observed were consistent with the known safety profile of the agent. The most common complain included transient genitourinary symptoms which might be due to TURBT. The symptoms did not worsen during the treatment process. No significant adverse effects related to OH2 irrigation was observed. Conclusions: OH2 injection is independently developed domestically and is the first in China to be used for intravesical irrigation therapy for recurrent high-risk NMIBC, particularly in patients who have failed BCG therapy. According to our data, OH2 injection intravesical irrigation is safe. The long term efficacy deserves further research. Clinical trial information: NCT05232136 .

Multivisceral surgery in patients with locally advanced castration-naïve and castration-resistant, symptomatic prostate cancer.

Journal of Clinical Oncology Julian Heidenreich, David Pfister, Constantin Rieger et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.176

176 Background: Local complications due to infiltration and compression of adjacent organs represent significant complications of locally advanced castration sensitive (CSPC) and castration resistant PCA (CRPC) despite the use of life prolonging agents. Methods: 139 patients with locally advanced CSPC/CRPC underwent palliative pelvic surgery: radical cystoprostatectomy in n=105 (75.5%), radical prostatectomy with continent vesicostomy in n=9 (6.5%) and anterior plus posterior exenteration in n=25 (17.6%). All patients underwent local staging via MRI of the small pelvis, cystoscopy and rectoscopy. Systemic staging was done with CT scans of the chest, abdomen, pelvis and bone scans. Perioperative complications were assessed according to Clavien-Dindo classification and symptom-free (SFS), cancer specific survival (CSS) were evaluated using the Kaplan-Meir method. Results: Indications for surgery were lower or upper urinary tract obstruction in 75 (54%) and 55 (39%), resp., hematuria and blood transfusions in 31 (22%), rectal infiltration with/without obstructive ileus in 23 (17%), refractory pelvic pain in 17 (12%). 96 (69%) pts had a combination of various symptoms. Clavien-Dindo grade 2, 3 and 4 complications developed in 32 (23%), 12 (8.6%) and 8 (5.7%), respectively. After a median follow-up of 42.5 (3 – 123) months, the SFS at 1 and 3 years was 90.3% and 66.9%. The median SFS was 27.9 months. CSS at 1 and 3 years was 92.2% and 43.7%, respectively. 78.6% of the patients were symptom-free during their remaining lifetime. Conclusions: Multivisceral prostate surgery is a technically feasible approach in well-selected patients resulting in symptom relief of > 90% of patients which covered almost 80% of the remaining life-time. Adequate preoperative imaging studies, endoscopic evaluation and extensive surgical experience is mandatory to achieving a benefit for the individual patient with improvement of quality of life.

Assessment of pathologic responses from unstructured pathology reports using large language models.

Journal of Clinical Oncology Swati Popli, Muhammad Umair Anjum, Syed Arsalan Ahmed Naqvi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.866

866 Background: Emerging data suggests that Language Models (LLMs) provide an unprecedented opportunity to extract critical data from the unstructured pathology reports. However, the performance of state of art (SOTA) models on clinically meaningful tasks such as assessment of pathologic responses in patients receiving neoadjuvant chemotherapy (NAC) in muscle invasive bladder cancer(MIBC) is not well known. Methods: This retrospective cohort included patients with pathologically confirmed Muscle-Invasive Bladder Cancer from the year 2018 to 2024. Selected patients included those who underwent Neoadjuvant chemotherapy followed by definitive cystectomy at Mayo Clinic. Gold standard labels were manually curated by trained clinicians. The state of the art (SOTA) LLM – GPT4 – was utilized using a structured zero-shot prompt to extract relevant phenotypic variables such as tumor site, tumor histology and additional histological variants if any, presence of in-situ / invasive carcinoma, presence of lamina propria / muscularis propria / lympho-vascular / perineural invasion, and T-stage from unstructured pathology reports. Structured prompts were iteratively developed for each data variable and validated using ~5% of the total dataset. The extracted variables were manually compared and labelled as True positive / True negative / False positive / False negative. Final performance was assessed against a held-out expert annotated test dataset using evaluation metric (accuracy). Results: A total of 200 reports from 99 patients were extracted by the LLM. Of the 200 reports, 41 duplicate / other pathology reports (e.g. – autopsy, cholecystectomy, etc.) were removed during final assessment. Significant characteristics such as tumor site, histology, and additional histology variant had an accuracy of 89%, 87%, and 91% respectively. Notably, accuracy of detection of in-situ versus invasive carcinoma was 70% versus 91%. Specific variables such as lamina propria / muscularis propria invasion / T-stage / lympho-vascular invasion / perineural invasion were answered with the accuracy of 75%, 75%, 67%, 90%, and 94% respectively. Conclusions: LLMs have the potential to extract critical data from unstructured pathology reports and automate assessment of pathologic responses in MIBC patients receiving NAC. Iterative improvements in performance can be achieved by improving prompt design using expert clinical input. This process can be potentially scaled to automate cancer registries.

Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment.

Journal of Clinical Oncology Allen Seylani, Peter D. Zang, Erasmus Poku et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.123

123 Background: Lutetium-177 vipivotide tetraxetan (Lu177) is the first FDA-approved radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Not much is known regarding the safety of dosing of Lu177 in patients with creatinine clearance outside the range included in VISION trial (Sartor et al.) which was ≥50 mL/min. Using an institutional database of patients treated with Lu177, we sought to analyze whether there were increased incidences of adverse events (AEs) in patients with impaired renal function who received Lu177. Methods: We retrospectively identified 58 patients with mCRPC who received Lu177 from 2022 - 2024 at a single center (City of Hope). Impaired renal function was defined as an eGFR ≤ 60 mL/min prior to initiation of Lu177 and not confounded by acute renal injury. Statistical analysis was performed using R (v.4.4.1). A Fisher’s Exact test was used to determine whether impaired renal function was associated with increased frequency of AEs. Results: Among the 58 patients, 28 (48.28%) were Caucasian/White, 19 (32.76%) were Latino/Hispanic, 6 (10.34%) were African American/Black, and 5 (8.62%) were Asian/Pacific Islander. Median age was 68.5 years old (40-86 years old). There were 6 patients with low GFR (37 to 60 ml/min) and 36 patients with normal GFR >60 mL/min. Both groups received standard pluvicto doses. In terms of AEs, the most common AEs were anemia (41.54%), thrombocytopenia (12.31%), xerostomia (10.77%), and fatigue (10.77%). For G3/G4 AEs, the most common were anemia (56.25%) and thrombocytopenia (18.75%). Only one patient with prior impaired renal function (GFR <60 mL/min) experienced deterioration of renal function. There was no significant difference noted in incidence of AEs, incidence of anemia, and incidence of G3/G4 anemia between those with impaired renal function and those with normal function (p = 1, p = 0.7119, p = 0.6649 respectively). Conclusions: Patients with GFR < 60 mL/min did not identify an increased incidence of AEs, including anemia, when treated with Lu177. Patients with impaired GFR experienced a similar AE profile (anemia, thrombocytopenia, and xerostomia) as described in prior data sets. Our findings suggest that Lu177 may be safely dosed in patients with impaired renal function as low as eGFR 37 mL/min, without significantly increasing the risk of AEs.

Health-related quality of life in patients with metastatic prostate cancer: Results from an international real-world survey.

Journal of Clinical Oncology Elena Castro, Suvina Amin, Alexander Niyazov et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.106

106 Background: Although novel treatments (tx) for metastatic prostate cancer (PC) are prolonging patient (pt) overall survival, data are limited on disease specific and general health-related quality of life (HRQoL) that can vary with pt disease stage and type of tx received. This analysis explores the HRQoL of pts diagnosed with metastatic castration-sensitive PC (mCSPC) and metastatic castration-resistant PC (mCRPC). Methods: Data were drawn from the Adelphi Real World Metastatic PC V Disease Specific Programme, an independent cross-sectional survey with retrospective data collection, of physicians and pts with mCSPC or mCRPC in France, Germany, Italy, Spain, the United Kingdom, and the United States from Nov’22 – Jul’23. Physicians reported pt demographics, clinical characteristics and tx history for their next four (mCSPC) and eight (mCRPC) consecutively seen pts. Pts voluntarily self-completed a survey including the EORTC QLQ-C30 and PR25. Pts with physician reported chart data, and an EORTC global health status/quality of life (GHS/QoL) score were included in analysis. Pt demographics, mean GHS/QoL and EORTC QLQ-C30/PR25 scale scores are reported descriptively. Results: Overall, 145 physicians reported data on 889 pts (median age 71 years (interquartile range 68 – 76), 75% ECOG 0–1, 88% had bone metastases and 24% visceral metastases). At data collection, 282 pts were receiving mCSPC tx, 482 first line (1L) mCRPC tx and 125 second line or later (2L+) mCRPC tx. Mean (SD) GHS/QoL scores for pts receiving mCSPC, 1L mCRPC and 2L+ mCRPC tx were 58.3 (19.9), 57.8 (17.7) and 55.5 (20.1) respectively, where high scores show high HRQoL. Of the symptom scales, pain was notable with mean (SD) scores of 29.9 (22.8) in mCSPC, 30.3 (20.6) in 1L mCRPC and 38.6 (23.6) in 2L+ mCRPC where high scores show worse symptomology. EORTC QLQ-C30/PR25 function scale scores are shown (Table). Conclusions: In pts who received life prolonging therapies for mCSPC and mCRPC, those with more advanced disease reported low HRQoL scores and high pain levels, suggesting that HRQoL remains an unmet need within the advanced disease setting. Metastatic prostate cancer patient EORTC QLQ-C30/PR25 function scale response. Function scales*mean (SD) mCSPC txn=282 1L mCRPC txn=482 2L+ mCRPC txn=125 Physical functioning 75.3(21.0) 75.7(18.7) 72.5(21.1) Role functioning 68.0(26.7) 69.3(23.7) 61.8(23.8) Emotional functioning 73.6(21.0) 75.9(20.6) 66.2(21.5) Cognitive functioning 80.0(21.9) 81.1(20.4) 77.0(21.8) Social functioning 75.0(24.2) 74.8(22.7) 65.5(25.7) Sexual activity 81.1(24.3) 81.4(23.9) 78.1(28.1) Sexual functioning 54.5(22.6) 57.2(21.1) 48.5(27.9) *High scores show high functioning. 1L: first line; 2L+: second line and later; mCSPC: metastatic castration-sensitive prostate cancer; mCRPC: metastatic castration-resistant prostate cancer; SD: standard deviation; tx: treatment.

Real-world outcomes of nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.

Journal of Clinical Oncology Jacob A. Moyer, Adri Durant, Mimi Nguyen et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.716

716 Background: Nadofaragene firadenovec is an FDA-approved gene therapy for Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) with promising clinical trial results. However, real-world post-marketing efficacy or safety data remain lacking. We evaluated complete response rates and safety in a multisite experience. Methods: Per IRB protocol, we analyzed patients treated with nadofaragene firadenovec for BCG-unresponsive NMIBC across three Mayo Clinic sites. Outcomes included complete response (CR), high-grade recurrence-free survival (HGRFS), cystectomy-free survival (CFS), overall survival (OS), and adverse events (AEs). CR and HGRFS were reported for patients with carcinoma in situ (CIS) and patients with Ta/T1 without CIS respectively. Failure to retain was defined as any medication loss, including leakage around the catheter or early voiding. Results: Between November 2023 and October 2024, 45 patients were treated with nadofaragene firadenovec for BCG-unresponsive NMIBC. Fifteen patients with follow-up less than 6 months and one patient with extensive metastatic disease identified one week after first instillation were excluded from efficacy analysis. Our efficacy-evaluable population of 29 patients with median follow-up of 8.2 months is summarized in the Table. CR/HGRFS at 3 and 6 months was 72% and 62% respectively. CFS was 94% and OS was 100% at 6 months. Three patients experienced disease progression during follow-up: one to T1, another to T2, and a third with metastases to the abdomen and lungs. A separate patient developed a metachronous upper tract urothelial carcinoma (pT2) without bladder recurrence. Bladder spasms (62%) and failure to retain (31%) were the most common AEs. Most AEs were low-grade, although four (9%) patients had grade 3 events (fatigue, fever, and dizziness). No grade 4-5 AEs were reported. Conclusions: Early real-world data demonstrates encouraging clinical complete response rates in patients with BCG-unresponsive NMIBC and a favorable safety profile. Further investigation with larger cohorts and longer follow-up is warranted. Evaluable patients (N=29) CIS cohort (N=15) Ta/T1 only cohort (N=14) Prior pembrolizumab (N=9) Prior intravesical chemotherapy (N=16) Age, years 72 (67-77) 74 (69-77) 71 (67-77) 69 (67-78) 73 (67-81) Elixhauser Index 5 (4-6) 5 (4-7) 5 (4-6) 5 (3-5) 5 (3-6) Prior BCG instillations 12 (10-14) 12 (12-15) 11 (8-13) 12 (12-12) 12 (11-13) Prior intravesical chemotherapy among recipients 6 (6-11) 6 (6-10) 6 (6-11) 10 (7-12) 6 (6-11) Prior pembrolizumab doses among recipients 7 (4-8) 8 (7-8) 4 (4-4) 7 (4-8) 8 (5-8) Follow-up, months 8.2 (6.9-9.5) 7.6 (6.9-9.5) 8.5 (6.9-9.4) 9.1 (8.0-10.1) 8.6 (6.7-9.9) 3-month CR/HGRFS 72% [53-87] 73% [45-92] 71% [42-92] 67% [30-93] 56% [30-80] 6-month CR/HGRFS 62% [42-79] 67% [38-88] 57% [29-82] 44% [14-79] 44% [20-70] Data are median (IQR) or % [95% CI].

Mature phase 1 follow up of alpha emitter 225Ac-J591 with 177Lu-PSMA-I&T in advanced prostate cancer.

Journal of Clinical Oncology Gabriel Raab, Tobechukwu Joseph Okobi, Aaron N. Holmes et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.185

185 Background: Targeted radionucleotide therapy (TRT) has become a standard of care. α-emitters have a higher energy transfer over a shorter range than β-emitters. PSMA-targeting antibodies have different biodistribution than small molecules and may improve intracellular retention based on pre-clinical models. Here, we present mature follow up of a phase 1 dose-escalation trial of 225Ac-J591 plus 177Lu-PSMA-I&T (aka PNT2002). Methods: Inclusion criteria:progressive mCRPC with ≥1 prior AR pathway inhibitor (ARPI), prior chemo (or unfit/refused), and with ≥1 lesion on PSMA PET where SUVmax >liver. 177Lu-PSMA-I&T (6.8 GBq) and 225Ac-J591 (30, 35, or 40 KBq/kg) given up to 2 doses 8 weeks apart. Primary outcome was dose-limiting limiting toxicity and recommended phase 2 dose (RP2D). Preliminary efficacy outcomes examined were overall survival (OS), progression-free survival (PFS), PSA response, and circulating tumor cell (CTC) changes. Results: 18 patients (6 at each dose level) with median age 70, median PSA of 54.4 (2.43-9614). Previous therapies: 11 (61%) with >1 ARPI, 12 (67%) chemo, 5 (28%) sip-T, 3 (17%) radium-223. Baseline CTCs: 15 detectable, 9 unfavorable. The median SUVmax of the most avid lesion on PSMA-PET was 31.4 (95% CI 11-82.7). Metastatic sites: 13 bone, 9 lymph node, 4 visceral. 8 (44%) were Halabi high risk. Treatment emergent adverse events (AEs) included neutropenia in 3 patients (17%), all Grade <2; thrombocytopenia occurred in 12 (67%) (3 GR 3); anemia in 10 (56%, 3 GR 3); 12 (67%) xerostomia (one Gr2); one (6%) with acute renal failure. Other AEs: 10 (56%) pain flare (1 Gr3 in pt with cord compression), 11 (61%) nausea (all Gr 1), 9 (50%) fatigue (all Gr 1). The RP2D of 225Ac-J591 was 35 KGBq/kg. 17 (94%) patients experienced a decline in PSA levels, with 11 out of 17 (64%) achieving PSA50 response. 4/5 patients (80%) converted from unfavorable to favorable CTC count, 4/8 (50%) from detectable to undetectable, 1 of 2 (50%) remained undetectable. Median biochemical PFS was 7.3 months (95% CI 2.7-15.8), and median OS was 29.8 mo (95% CI 7.4-NR), with 10 patients still alive at time of submission. 5 were progression free at one year, including 3 of 6 treated at RP2D. With longer follow up, no new safety signals were identified. Conclusions: The combination of PSMA-targeted alpha (via antibody) plus beta (via small molecule) was feasible. High grade AEs were rare and no new safety signals emerged with longer term follow up. Nearly all patients had PSA decline, and 5 had durable disease control off therapy. Clinical trial information: NCT04886986 .

Optimizing the strategies to perform prostate biopsy in MRI-positive patients: A systematic review and network meta-analysis.

Journal of Clinical Oncology Qiyou Wu, Xiang Tu, Bo Tang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.340

340 Background: Prostate cancer (PCa) is the most commonly diagnosed cancer in men, and early detection is crucial for better patient outcomes. This study aimed to thoroughly compare existing biopsy schemes for patients with suspicious lesions. Methods: This study conducted a systematic review and network meta-analysis following PRISMA guidelines, evaluating 13 biopsy schemes for detecting PCa in MRI-positive patients. Data from PubMed, Embase, and Cochrane databases were examined to assess the efficacy of biopsy schemes in detecting clinically significant (csPCa) and clinically insignificant (ciPCa) prostate cancer. Results: The analysis included 188 studies involving 64637 individuals. When compared with the combination of systematic biopsy (SB) and targeted biopsy (TB) (SB+TB), ipsilateral SB with TB (ips-SB+TB) and saturation TB (≥ 6 cores TB with or without perilesional cores) had comparable detection rate of csPCa (ips-SB+TB: RR 0.94, 95%CrI 0.87, 1.0; saturation TB: RR 0.94, 95%CrI 0.89, 1.0). While, saturation SB+TB and SB saturation (> 20 cores SB) detected slightly more csPCa than SB+TB (saturation SB+TB: RR 1.04, 95%CrI 0.97, 1.11; saturation TB: RR 1.09, 95%CrI 0.93, 1.29). And TB and SB alone detected significantly less csPCa than SB+TB (TB: RR 0.86, 95%CrI 0.84, 0.88; SB: RR 0.74, 95%CrI 0.72, 0.76). Saturation SB also did not show significant superiority in detecting csPCa. Additionally, saturation TB and ips-SB+TB also decrease the detection of ciPCa. (ips-SB+TB: RR 0.87, 95%CrI 0.73, 1.04; saturation TB: RR 0.81, 95%CrI 0.70, 0.94). The SUCRA results are detailed (Table). Conclusions: The network meta-analysis underscores that saturation SB+TB and SB+saturation TB can detect the most PCa. While, ips-SB+TB and saturation TB are effective biopsy strategies for MRI-positive PCa patients, offering a more targeted approach, improving diagnostic accuracy. Ranking probability of different biopsy schemes. PCa csPCa ciPCa Biopsy schemes Cumulative Probability Biopsy schemes Cumulative Probability Biopsy schemes Cumulative Probability 1 SB+saturation TB 0.936 SB+saturation TB 0.954 SB+saturation TB 0.958 2 saturation SB+TB 0.920 saturation SB+TB 0.922 saturation SB+TB 0.910 3 SB+TB 0.840 SB+TB 0.842 saturation SB 0.768 4 ips-SB+TB 0.621 ips-SB+TB 0.682 SB+TB 0.739 5 saturation SB 0.590 saturation TB 0.675 ips-SB+TB 0.520 6 saturation TB 0.536 non-targeted SB+TB 0.549 con-SB+TB 0.427 7 non-targeted SB+TB 0.524 saturation SB 0.489 non-targeted SB+TB 0.424 8 con-SB+TB 0.470 con-SB+TB 0.487 SB 0.392 9 TB 0.240 TB 0.401 saturation TB 0.381 10 SB 0.229 SB 0.250 ips-SB 0.306 11 ips-SB 0.096 ips-SB 0.143 con-SB 0.089 12 con-SB 0.000 adjacent sextant SB 0.108 TB 0.085 13 con-SB 0

Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.

Journal of Clinical Oncology Nicholas David James, Joseph van de Wiel, Ana Hughes et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.778

778 Background: Immune checkpoint inhibitors have a substantial and growing role in all stages of care for bladder cancer. Durvalumab (Durva) is a humanised monoclonal antibody that inhibits binding of PD-L1. Recent phase 3 results with peri-operative durvalumab show a 25% reduction in the risk of death compared to standard of care. Methods: RADIO is a multi-stage trial comparing standard chemoradiotherapy (CRT) with 5FU & mitomycin C (MMC) +/- durvalumab given pre-CRT x1, during CRT x1 and post CRT for up to 12 months. Eligible patients T2-T4aN0-2M0 bladder cancer, neo-adjuvant chemotherapy was encouraged for suitable participants. Switch to single arm occurred after achieving feasibility criteria. We report here feasibility and toxicity data up to 3 months post randomisation. Recruitment continues in the single arm efficacy phase with results to be reported later. Results: Between Oct 2020 and May 2023, 29 participants were randomised. Median age 68 (IQR 61-75) years, 26 male, 3 female. Casemix: T2N0 21 (72.4%), T3N0 8 (27.6%), T4N0 0 (0%). 23 (79.3%) had received prior neoadjuvant chemotherapy. 10 (34.5%) were recruited to receive CRT only, 19 (65.5%) to receive CRT + Durva. All participants completed 55Gy/20# RT, 25 (86.2%) without any delays and 4 participants completed RT but with delay (1-5 days), 2 due to toxicity, 2 due to external factors. Median intensity of planned dose received: RT; 1 (IQR 1-1), MMC; 0.97 (IQR 0.94-0.99), 5FU; 0.8 (IQR 0.49-0.96), Durva; 0.97 (IQR 0.88-1). Toxicity for patients on the CRT + Durva arm, between informed consent and 3 months post the end of CRT:6 SAEs were reported, 3 of which were SARs and 0 were SUSARs. Of these SAEs, 3 were related to trial treatment (2 related to Durva, 2 related to 5FU & MMC, 1 being related to both regimens), 3 lead to discontinuation (RT; 0, MMC; 0, 5FU; 2, Durva; 1), and 2 SAEs lead to dose delays (RT; 0, MMC; 0, 5FU; 0, Durva; 2). In the CRT + Durva arm there were 9 AEs grade ≥3 (6 related to trial treatment). Results split by CRT only or CRT + Durva will be available at the time of the conference, and all figures are provisional on subsequent rounds of data cleaning. Conclusions: The schedule of neo-adjuvant, synchronous and adjuvant durvalumab was deliverable with full dose CRT to bladder. Most participants completed CRT as planned, none discontinued Durva due to toxicity, only 3 incurred toxicity related delays but continued treatment. Clinical trial information: 43698103.

GLP-1 analogues and prostate cancer incidence: A systematic review and meta-analysis.

Journal of Clinical Oncology Selena Gong, Eric Yu, Tanvir Chakkal et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.374

374 Background: Preliminary evidence from preclinical and observational data suggests that GLP-1 receptor agonists (GLP-1RAs) may reduce prostate cancer (PCa) incidence. We aimed to assess the effects of GLP-1RAs on PCa risk. Methods: Embase, Medline, Web of Science, and Cochrane databases were searched from inception to identify phase III randomized controlled trials (RCTs) comparing a GLP-1 RA with placebo/non-GLP-1 RA regimens. The primary outcome was incidence of PCa. A Mantel-Haenszel random-effect meta-analysis was carried out to estimate the pooled relative risk (RR) and 95% confidence interval (CI) for the occurrence of PCa among male participants. Results: Of the 27,103 abstracts identified, 56 trials including 59,334 male participants were included. Eligibility included type 2 diabetes mellitus in 48 studies, obesity in 7 studies, and heart failure in 1 study. The GLP-1 RA’s studied included liraglutide (18), semaglutide (13), dulaglutide (6), albiglutide (6), lixisenatide (5), exenatide (4), and others (5). One study included both liraglutide and semaglutide as interventions. Follow-up durations ranged from 12 weeks to 260 weeks (5 years), with a mean of 72.5 weeks (standard deviation = 50.85). The pooled incidence of PCa was 0.55% (150 of 27,126) for the control group and 0.46% (148 of 32,208) for the GLP-1 intervention group. The pooled RR of PCa incidence with all GLP-1 RAs compared to controls was 0.86 (95% CI: 0.69-1.06, p=0.16). Conclusions: There were proportionally fewer incident PCa cases among GLP-1 RA recipients as compared with control. However, this did not achieve statistical significance. Trials were limited in duration and by the lack of pre-specification of this outcome. Further research is needed to evaluate whether GLP-1 RAs have activity against established PCa.

Timely next-generation sequencing testing in patients with metastatic prostate cancer: A comparative analysis between Medicare Advantage and traditional Medicare.

Journal of Clinical Oncology Jonathan Wenbin Ji, Baqir Jafry, Chuan Angel Lu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.320

320 Background: Next-Generation Sequencing (NGS) testing has become a cornerstone of personalized medicine in cancer care. With Medicare Advantage (MA) now covering nearly half of all beneficiaries, understanding differences in access to timely NGS testing between MA and Traditional Medicare (TM) is crucial, particularly given MA’s potential restrictions. This study aims to evaluate the effectiveness of MA plans on timely NGS testing in patients with metastatic prostate cancer (mPCa). Methods: This retrospective cohort study was based on the Flatiron Health deidentified Database, comprising electronic health record-derived data from ~280 cancer practices across the US. Our study included patients aged 65 or older, diagnosed with mPCa since 2018, and exclusively enrolled in TM or MA, either before or within 90 days following mPCa diagnosis. We compared the rates between TM and MA, using three timeframes—45-, 90-, and 180-days post-mPCa diagnosis. NGS testing was defined as any tissue or liquid genomic testing resulted within the time frame of interest. Multivariate logistic regression with inverse probability of treatment weighting was used, adjusting for demographics, year of mPCa diagnosis, practice setting, and baseline ECOG score. Results: Among the 1,582 MA patients (mean age: 75.9 ± 5.8) and 2,749 TM patients (mean age: 75.4 ± 5.8), significant proportions were from community practice (MA: 78%, TM: 80%) and were characterized by being White (MA: 59%, TM: 65%), aged 75 to 85 (MA: 54%, TM: 57%), having higher socioeconomic status (SES 4 or 5: MA: 40.3%, TM: 47.5%), presenting with de-novo mPCa (MA: 53%, TM: 54%), and having better baseline functional performance (ECOG 0 or 1: MA: 70%, TM: 69%). Since 2018, 8.8%, 14.5%, 18.8% of MA patients and 10%, 14.6%, 17.6% of TM patients received NGS testing at 45, 90 and 180 days, respectively. Notably, 63.4% and 60.8% of MA and TM patients, respectively, did not have any NGS testing. After adjusting for covariation, MA was associated with a 26.2% (OR=0.74, 95%CI 0.59-0.92), 16% (OR=0.84, 95%CI 0.7-1.01), 7.8% (OR=0.92, 95%CI 0.78-1.09) lower chance to receive timely NGS testing at 45 days, 90 days and 180 days, respectively. Conclusions: Patients with mPCa enrolled in MA are less likely to receive timely NGS testing compared to TM. The high rate of delayed or no testing underscores disparities in access, especially among MA patients. Policymakers should streamline approvals to ensure timely, high-quality care for all Medicare beneficiaries.

DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer.

Journal of Clinical Oncology Michal Sternschuss, Alexander Paynter, Wenxin Xu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.853

853 Background: DNA damage repair gene alterations (DDRa), especially ERCC2 mutations, have been associated with improved clinical outcomes in patients with urothelial cancer (UC) treated with cisplatin-based neoadjuvant chemotherapy. The predictive value of DDR alterations for platinum-based chemotherapy in metastatic disease is not well-defined. Methods: We analyzed the American Association of Cancer Research (AACR) Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative consortium (BPC), including patients with UC treated at 4 academic centers in North America between 2013 and 2018, with Next Generation Sequencing (NGS) data available. We assessed overall survival among patients treated with first line platinum-based chemotherapy for metastatic UC, and compared the outcomes based on DDRa status using Cox models adjusted with risk-set adjustment for delayed entry. DDRa were defined as any mutation defined as “likely oncogenic” or “oncogenic” in OncoKB for the genes ERCC2, ERCC5, BRCA1, BRCA2, RECQL4, ATM, ATR, RAD51C and FANCC . Results: Of 716 patients with UC, 103 (14%) had any DDRa, and 32 (4.5%) had an ERCC2 mutation. Among 566 patients (79%) who developed metastatic disease at any time during follow up, median age was 66 years, 22% were female and 25% had upper tract UC. The median overall survival (mOS) from diagnosis of metastatic disease was 15.1 months (95% CI 12.6-18.6). For patients treated with first line platinum-based chemotherapy (n=258), the presence of DDRa was associated with significantly improved mOS compared with absence of DDRa: 22.7 versus 11.2 months, hazard ratio (HR) 0.54 (95% CI 0.34-0.86, p=0.009). Similar trends were seen when analyzing patients treated with cisplatin or carboplatin, separately. Conclusions: DDRa were associated with improved survival in metastatic UC patients treated with platinum-based chemotherapy. Further studies are needed to explore the prognostic and predictive value of DDRa as the role of platinum-based chemotherapy evolves in the enfortumab vedotin and pembrolizumab era. DDRa No DDRa First Line treatment for metastatic UC N Median OS months (95% CI) N Median OS months (95% CI) HR (95% CI) P value Any platinum-based chemotherapy 32 22.7 (14.5, 66.9) 226 11.2 (9.4, 15.1) 0.54 (0.34, 0.86) 0.009  Cisplatin-based chemotherapy 22 25.9 (14.5, NR) 142 13.6 (10.4, 18.8) 0.57 (0.32, 1.01) 0.06  Carboplatin- based chemotherapy 10 17.4 (7.26, NR) 84 9.9 (6.6, 12.7) 0.53 (0.25, 1.17) 0.12 CI= Confidence interval; DDRa= DNA damage repair alteration; HR=Hazard ratio; NR=Not reached; OS= Overall survival; UC= Urothelial Carcinoma.

Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.

Journal of Clinical Oncology Hedyeh Ebrahimi, Luis A Meza, Nazli Dizman et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.543

543 Background: We previously reported that combining CBM588 ( Clostridium butyricum MIYAIRI588), a live bacterial product, with cabozantinib (cabo) and nivolumab (nivo) enhanced clinical benefit in treatment-naïve patients with mRCC (Ebrahimi et al ; Nature Medicine 2024). The current study provides updated clinical data to further evaluate the potential benefits of CBM588 in combination with cabo/nivo. Methods: This open-label, randomized trial enrolled patients aged ≥18 years old with a Karnofsky performance status ≥70% and histologically verified (clear-cell, papillary or sarcomatoid component) advanced or mRCC with no prior systemic therapy for metastatic disease. Patients were randomized in a 1:2 ratio to receive either cabo/nivo (40mg PO QD and 480mg IV monthly, respectively) alone or with CBM588 (80mg PO BID). This analysis provides updated secondary clinical endpoints with extended follow-up, including overall response rates (ORR), progression-free survival (PFS), and toxicity. Clinical benefit was defined as complete response, partial response, or stable disease, per RECIST 1.1. The association between treatment arm and ORR was evaluated using Fisher’s exact test, and PFS was estimated using the Kaplan-Meier method. Results: A total of 30 patients (20:10 M:F) were recruited, with a median age of 65 years (range, 36-84). Five patients (17%) had sarcomatoid features, and two (7%) had predominant papillary histology. As of June 1, 2024, the median follow-up was 25.8 months (interquartile range, 19.2-28.1) in the overall cohort. The ORR was significantly higher in the CBM588-containing arm compared to cabo/nivo alone arm (79% versus 20%, P =0.004). In the CBM588 arm, 17 (89%) patients, and in the control arm, 8 (80%) patients had a reduction in target lesion size, with median decreases of 51% (range, 17-94%) and 22% (range, 13-100%), respectively. Clinical benefit for at least 6 months was achieved in 80% of patients treated in experimental arm and 60% patients in the control arm. The median PFS was not reached in patients receiving CBM588, compared to 13.4 months in the control arm. The median OS was not reached in either of the arms at the time of data cutoff. Grade 3 or higher treatment-related adverse events (TRAEs) were observed in 45% of the CBM588 arm compared to 40% in the control arm. The most common TRAEs in the overall cohort were transaminitis (10%), hypertension (7%), and diarrhea (7%), with no significant differences between treatment arms. No new safety signals were detected. Conclusions: The addition of CBM588 to cabo/nivo continues to show promising efficacy in mRCC, with an improved PFS and ORR. The safety profile remains consistent with previous findings, supporting further exploration in larger trials. Further translational efforts are underway to characterize the mechanism through which CBM588 augments clinical activity. Clinical trial information: NCT05122546 .

Evaluating the therapeutic role of lymph node dissection in variant histology bladder cancer.

Journal of Clinical Oncology Syed Rahman, David Hesse, Michael Jalfon et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.749

749 Background: Outcome benefit associated with lymph node dissection (LND) at time of radical cystectomy have been suggested in urothelial bladder cancer (BC), but have not been evaluated in variant subtype BC. Our objective was to characterize the impact of LND on survival outcomes across variant subtype BC. Methods: The National Cancer Database was queried for cases of variant histology bladder cancers using International Classification of Disease-O-3 morphologic codes managed with radical cystectomy between 2004 and 2020. Cases were stratified by variant subtype and LND status. Primary outcome was overall survival associated pathologic nodal status and receipt of LND. Kaplan Meier analysis and Cox proportional hazards analysis were performed for survival analyses. Results: A total of 30,911 patients with variant UC histology were included in our analysis. that were managed with radical cystectomy. Rates for the no-LND group (pNx) were 33.1% in the micropapillary subtype, 42.2% in sarcomatoid, 68.4% in squamous, 48.9% in adenocarcinoma, and 56.2% in the neuroendocrine subtype. Median OS was higher in those that received a nodal dissection for squamous (91.3 [89.9, 92.7] vs. 62.8 [60.1, 65.6] months p<0.001) and adenocarcinoma (83.6 [73.1, 92.1] vs. 56.3 [43.5, 69.0] months p=0.020). On Cox proportional hazards regression, in T1/2 stage disease LN dissection was associated improved OS for sarcomatoid (0.50 [0.23-0.96] p=0.048), squamous (0.67 (0.61-0.76) p<0.001), adenocarcinoma (0.45 [0.23-0.85) p=0.015), and neuroendocrine (0.425 [0.21-0.85) p=0.017) variant histologies. In T3/4 disease, nodal dissection was statistically significant improved OS only for squamous histology (0.68 [0.59-0.77] p<0.001 and 0.70 [0.59-0.83] p<0.001 respectively). The survival benefit of LND appears to be attenuated following receipt of NAC across most histologic subtypes including micropapillary and sarcomatoid histologies. Conclusions: Our data highlights the varying degrees of therapeutic benefit across variant BC. LND particularly in sarcomatoid, neuroendocrine, and adenocarcinoma VHBC is correlated with improved survival, particularly in low clinical stages. The benefit also appears to be attenuated with receipt of NAC. These data help inform a variant subtype-informed surgical approach.

Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).

Journal of Clinical Oncology Toni K. Choueiri, Todd Michael Bauer, Jaime R. Merchan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.549

549 Background: In the phase 2 LITESPARK-003 study (NCT03634540), belzutifan plus cabozantinib showed antitumor activity in patients with advanced ccRCC who were treatment-naive (cohort 1) or previously treated (cohort 2). We present updated results from cohorts 1 and 2 with a median follow-up of 34.4 months and 49.9 months, respectively. Methods: Eligible patients had advanced or metastatic ccRCC and ECOG performance status of 0 or 1. Cohort 1 included patients with no prior systemic therapy. Cohort 2 included patients who had received prior immunotherapy and ≤2 systemic regimens. Starting doses for patients in both cohorts were belzutifan 120 mg PO QD + cabozantinib 60 mg PO QD. The primary end point was ORR per RECIST v1.1 by investigator assessment. Secondary end points included DOR, PFS, OS, and safety. Results: 50 patients were enrolled and treated in cohort 1 and 52 patients in cohort 2. Confirmed ORR was 70% (95% CI, 55-82; 6 CRs, 29 PRs) in cohort 1 and 31% (95% CI, 19-45; 2 CRs, 14 PRs) in cohort 2. In cohort 2, ORR was 32% (95% CI, 16-52; 1 CR, 8 PRs) in patients who received prior immunotherapy only (n = 28) and 29% (95% CI, 13-51; 1 CR, 6 PRs) in patients who received both prior immunotherapy and anti-VEGFR TKIs (n = 24). ORR by IMDC risk and baseline tumor burden subgroups is shown in the Table. Median DOR was 29.1 months (range, 1.9+ to 47.4; + indicates ongoing response at the last assessment) in cohort 1 and 30.4 months (range, 4.2+ to 45.6) in cohort 2. An estimated 62% of responders in cohort 1 and 52% in cohort 2 remained in response for ≥24 months. Median PFS was 30.3 months (95% CI, 19.4-not reached) in cohort 1 and 13.8 mo (95% CI, 9.2-19.4) in cohort 2. Median OS has not been reached in cohort 1 and was 26.7 months (95% CI, 20.0-41.1) in cohort 2. Overall, 27 (54%) patients in cohort 1 and 34 (65%) patients in cohort 2 had a grade 3 or higher treatment-related adverse event (TRAE). No patients died due to a TRAE in cohort 1 and 1 patient (2%) died due to treatment-related respiratory failure in cohort 2. Conclusions: With updated follow-up,belzutifan plus cabozantinib showed durable antitumor activity in both frontline and subsequent-line treatment of patients with RCC and a safety profile consistent with prior reports. These results support further investigation of a HIF-2α inhibitor in combination with a VEGFR-TKI as a treatment option for advanced ccRCC in both settings. Clinical trial information: NCT03634540 . Cohort 1 Cohort 2 IMDC risk category Favorable n = 33ORR, 73% (95% CI, 54-87); 5 CRs, 19 PRs n = 9ORR, 67% (95% CI, 30-93); 1 CR, 5 PRs Intermediate or poor n = 17ORR, 65% (95% CI, 38-86); 1 CR, 10 PRs n = 43ORR, 23% (95% CI, 12-39); 1 CR, 9 PRs Baseline tumor burden a Low (< median) n = 25ORR, 80% (95% CI, 59-93);3 CRs, 17 PRs n = 26ORR, 27% (95% CI, 12-48); 2 CRs, 5 PRs High (≥ median) n = 25ORR, 60% (95% CI, 39-79); 3 CRs, 12 PRs n = 26ORR, 35% (95% CI, 17-56); 0 CRs, 9 PRs a Based on the sum of diameter of the target lesions at baseline.